AER-271
规格
| Cas Number | 634913-39-6(DMSO) |
| 规格或纯度 | 10mM in DMSO |
| 包装 | 1ml |
产品信息
| 品牌 | 阿拉丁 |
| 浓度 | 10mM in DMSO |
| 过滤标签 | Aquaporin,膜转运器/离子通道,Compound libraries |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | AER-271是AER-270的一种膦酸盐原药衍生物，是一种用于研究急性缺血性中风的水通道蛋白-4（AQP4）抑制剂。 |
| 英文描述 |
AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 ( AQP4 ) inhibitor for the research of acute ischemic stroke In Vivo AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest . AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male mice (C57BL/6J, 8-12 week-old, 25-30 g)Dosage: 5 mg/kg Administration: Treated by i.p. injection Result: Had better outcomes with an average neurological score of 0.89±0.31 compared with control mice receiving vehicle had an average neurological score of 2.50±0.62. IC50& Target:Aquaporin-4 (AQP4) |